BRD9 and cancer: To date, a set of PROTACs, mostly based on the Cereblon E3 ligase recruiting moiety, have been developed for the degradation of BRD9 (Figure 1B), featuring promising outcomes in cancer therapies,[23, 24, 25, 26, 27, 28, 29, 30, 31, 32] and currently two degraders have entered clinical trials, namely FHD‐609 (NCT04965753) and CFT8634 (NCT05355753).[33] Unfortunately, the two clinical trials with BRD9 PROTACs were terminated, thus highlighting the urgent need of new BRD9 PROTACs.